Hans Georg Klingemann

US Patent:

20020068044, Jun 6, 2002

Filed:

Dec 7, 2001

Appl. No.:

10/008955

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K048/00
A61M037/00

US Classification:

424/093200, 424/140100, 604/005020

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20040018182, Jan 29, 2004

Filed:

Jun 6, 2003

Appl. No.:

10/456779

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K048/00

US Classification:

424/093210, 424/093700

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20040018183, Jan 29, 2004

Filed:

Jun 6, 2003

Appl. No.:

10/456829

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K048/00

US Classification:

424/093210, 424/093700

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20040022773, Feb 5, 2004

Filed:

Jun 6, 2003

Appl. No.:

10/456620

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K048/00

US Classification:

424/093210

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20040052770, Mar 18, 2004

Filed:

Jun 6, 2003

Appl. No.:

10/456237

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K048/00

US Classification:

424/093700, 424/093210

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20060110360, May 25, 2006

Filed:

Nov 4, 2003

Appl. No.:

10/701359

Inventors:

Hans Klingemann - Winnetka IL, US

International Classification:

A61K 35/14

US Classification:

424093100

Abstract:

This invention relates to a natural killer cell line termed NK-92. The invention provides a vector for transfecting a mammalian cell which includes a nucleic acid sequence encoding a cytokine that promotes the growth of NK-92. Additionally, the invention provides an NK-92 cell, or an NK-92 cell modified by transfection with a vector conferring advantageous properties, which is unable to proliferate and which preserves effective cytotoxic activity. The invention further provides a modified NK-92 cell that is transfected with a vector encoding a cytokine that promotes the growth of NK-92 cells. The cell secretes the cytokine upon being cultured under conditions that promote cytokine secretion, and furthermore secretes the cytokine in vivo upon being introduced into a mammal. In a significant embodiment, the cytokine is interleukin 2. The present invention also provides methods of purging cancer cells from a biological sample, of treating a cancer ex vivo in a mammal, and of treating a cancer in vivo in a mammal employing a natural killer cell, such as NK-92 itself, an NK-92 cell which is unable to proliferate and which preserves effective cytotoxic activity, or natural killer cells transfected with a vector encoding a cytokine.

US Patent:

20090170059, Jul 2, 2009

Filed:

Nov 14, 2006

Appl. No.:

12/084931

Inventors:

Hans Klingemann - Boston MA, US

International Classification:

A01N 1/02
C12N 5/06
C12N 5/08
C12N 15/87

US Classification:

435 13, 435374, 435366, 435455

Abstract:

Methods and kits are provided for preparation of umbilical cord fragments and cells using autologous blood or blood products, and for storage of these materials with autologous cells and blood or blood products in containers having a plurality of separable chambers.

US Patent:

20200123503, Apr 23, 2020

Filed:

Jan 5, 2018

Appl. No.:

16/475926

Inventors:

- San Diego CA, US
Hans Klingemann - Boston MA, US

Assignee:

NANTKWEST, INC. - San Diego CA

International Classification:

C12N 5/0783
C12N 15/113
C07K 14/725
C07K 14/735
C12N 9/22
C12N 15/86
A61K 35/17
C12N 15/11

Abstract:

Provided are CD96-modified and TIGIT-modified NK-92 cells comprising one or more alterations that inhibit expression of CD96 and/or TIGIT. Also provided are methods of generating such modified NK-92 cells and methods of treating a subject having or suspected of having a cancer using the modified NK-92 cells.